medigraphic.com
SPANISH

Medicina Interna de México

Colegio de Medicina Interna de México.
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2019, Number 4

<< Back Next >>

Med Int Mex 2019; 35 (4)

Pharmacological treatment of diabetes mellitus type 2 directed to patients with overweight and obesity

Mellado-Orellana R, Salinas-Lezama E, Sánchez-Herrera D, Guajardo-Lozano J, Díaz-Greene EJ, Rodríguez-Weber FL
Full text How to cite this article

Language: Spanish
References: 0
Page: 525-536
PDF size: 203.05 Kb.


Key words:

Diabetes mellitus type 2, Weight loss, Glycated hemoglobin, Obesity.

ABSTRACT

Diabetes mellitus type 2 (DM2) is a chronic and multifactorial disease that requires an integral treatment throughout the life of the patient and in need of constant adjustments according to specific requirements of each patient. It is well established that weight loss in diabetic patients may delay the progression of the disease or even delay its onset. In addition to being a beneficial factor in the treatment goals of diabetic patients, weight reduction can achieve clinically significant changes in serum glucose, glycated hemoglobin (HbA1c) and triglyceride levels. Evidence-based recommendations are currently aimed at pharmacological, surgical and lifestyle changes in the management of obesity as part of the comprehensive treatment of patients with diabetes mellitus type 2. Traditional pharmacological treatments for diabetes mellitus type 2 may further increase weight and this may decrease the benefits of adequate glycemic control. It’s important to identify the interference of each drug group on weight.





2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Med Int Mex. 2019;35